Suchergebnisse - "van der Togt, Céleste J T"

PubPharm (5)

1

Disease activity-guided dose optimisation including discontinuation of TNF-inhibitors in rheumatoid arthritis is effective for up to 10 years : an observational follow-up of the DRESS study

enthalten in: Rheumatology (Oxford, England) | 2024

von van der Togt, C. | den Broeder, N. | Boonstra, M. | +3

2

Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis

enthalten in: Rheumatology (Oxford, England) | 2023

von van der Togt, C. | Ten Cate, D. | van den Bemt, B. | +3

3

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases : results from an umbrella review and international Delphi study

enthalten in: RMD open | 2023

von van der Togt, C. | Van den Bemt, B. | Aletaha, D. | +10

4

Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis

enthalten in: Rheumatology (Oxford, England) | 2022

von van der Togt, C. | Ten Cate, D. | den Broeder, N. | +3

5

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)

enthalten in: Therapeutic advances in musculoskeletal disease | 2022

von van der Togt, C. | Verhoef, L. | van den Bemt, B. | +3

1
[1]